Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-64
Last updated

Report documents

  1. Extract of dossier assessment

    Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 237 kB, EN, PDF
    DOI-Link
    https://doi.org/10.60584/A24-64_en
    Download file : Extract of dossier assessment (PDF-Dokument, 237 kB, EN, PDF)

  2. Dossier assessment

    Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 454 kB, DE, PDF
    DOI-Link
    https://doi.org/10.60584/A24-64
    Download file : Dossier assessment (PDF-Dokument, 454 kB, DE, PDF)

Dossier assessment

Indication:

Adult patients with active moderate to severe hidradenitis suppurativa (acne inversa) with an inadequate response to conventional systemic hidradenitis suppurativa therapy

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2024-11-22 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A24-64
Commission
Commission awarded on 17.05.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI
https://doi.org/10.60584/A24-64_en

Connected Projects

  1. Dossier assessment

    Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-60
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-61
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-110
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-62
    Last updated

    Status: Commission completed

  5. Addendum

    Bimekizumab (hidradenitis suppurativa) - Addendum to Project A24-64

    Project no.
    G24-28
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page